Adjuvant and salvage radiotherapy after prostatectomy: American Society of Clinical Oncology clinical practice guideline endorsement

Journal of Clinical Oncology

Volumn 32, Issue 34, 2014, Pages 3892-3898

  Freedland, Stephen J ^a   Rumble, R Bryan ^c   Finelli, Antonio ^d   Chen, Ronald C ^b   Slovin, Susan ^f   Stein, Mark N ^g   Mendelson, David S ^h   Wackett, Colin ^e   Sandler, Howard M ⁱ  

^a DUKE UNIVERSITY   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

^c AMERICAN SOCIETY OF CLINICAL ONCOLOGY   (United States)

^d PRINCESS MARGARET HOSPITAL   (Canada)

^e Memorial Sloan Kettering Cancer Center ^*  (Canada)

^f MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^g RUTGERS CANCER INSTITUTE OF NEW JERSEY   (United States)

^h Pinnacle Oncology Hematology   (United States)

ⁱ CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN; KALLIKREIN; KALLIKREIN-RELATED PEPTIDASE 3, HUMAN;

ADJUVANT THERAPY; ARTICLE; CANCER RADIOTHERAPY; CLINICAL PRACTICE; DISEASE COURSE; GLEASON SCORE; HUMAN; MALE; META ANALYSIS (TOPIC); PATIENT COUNSELING; PRACTICE GUIDELINE; PROSTATE CANCER; PROSTATECTOMY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK BENEFIT ANALYSIS; SALVAGE THERAPY; SEMINAL VESICLE; BLOOD; ONCOLOGY; PATHOLOGY; PATIENT SELECTION; PREDICTIVE VALUE; PROSTATIC NEOPLASMS; RISK FACTOR; STANDARDS; TREATMENT OUTCOME; TUMOR RECURRENCE;

DISEASE PROGRESSION; HUMANS; KALLIKREINS; MALE; NEOPLASM RECURRENCE, LOCAL; PATIENT SELECTION; PREDICTIVE VALUE OF TESTS; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; RADIATION ONCOLOGY; RADIOTHERAPY, ADJUVANT; RISK FACTORS; SALVAGE THERAPY; TREATMENT OUTCOME;

EID: 84912097640     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2014.58.8525     Document Type: Article

References (9)

1. Siegel R, Ma J, Zou Z, et al: Cancer statistics, 2014. CA Cancer J Clin 64:9-29, 2014
2. Thompson IM, Valicenti RK, Albertsen P, et al: Adjuvant and salvage radiotherapy after prostatectomy: AUA/ASTRO guideline. J Urol 190:441-449, 2013
3. Moreira DM, Presti JC Jr, Aronson WJ, et al: Natural history of persistently elevated prostate specific antigen after radical prostatectomy: Results from the SEARCH database. J Urol 182:2250-2255, 2009
4. Abdollah F, Suardi N, Cozzarini C, et al: Selecting the optimal candidate for adjuvant radiotherapy after radical prostatectomy for prostate cancer: A long-term survival analysis. Eur Urol 63:998-1008, 2013
5. Arlen PM, Bianco F, Dahut WL, et al: Prostate specific antigen working group guidelines on prostate specific antigen doubling time. J Urol 179:2181-2185, 2008; discussion 2185-2186
6. Stephenson AJ, Shariat SF, Zelefsky MJ, et al: Salvage radiotherapy for recurrent prostate cancer after radical prostatectomy. JAMA 291:1325-1332, 2004
7. Freedland SJ, Humphreys EB, Mangold LA, et al: Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. JAMA 294:433-439, 2005
8. Trock BJ, Han M, Freedland SJ, et al: Prostate cancer-specific survival following salvage radiotherapy vs observation in men with biochemical recurrence after radical prostatectomy. JAMA 299:2760-2769, 2008
9. Moreira DM, Presti JC Jr, Aronson WJ, et al: Postoperative prostate-specific antigen nadir improves accuracy for predicting biochemical recurrence after radical prostatectomy: Results from the Shared Equal Access Regional Cancer Hospital (SEARCH) and Duke Prostate Center databases. Int J Urol 17:914-922, 2010